JP2002512989A5 - - Google Patents

Download PDF

Info

Publication number
JP2002512989A5
JP2002512989A5 JP2000545584A JP2000545584A JP2002512989A5 JP 2002512989 A5 JP2002512989 A5 JP 2002512989A5 JP 2000545584 A JP2000545584 A JP 2000545584A JP 2000545584 A JP2000545584 A JP 2000545584A JP 2002512989 A5 JP2002512989 A5 JP 2002512989A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
halogen
con
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000545584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512989A (ja
JP4648542B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/008905 external-priority patent/WO1999055388A1/en
Publication of JP2002512989A publication Critical patent/JP2002512989A/ja
Publication of JP2002512989A5 publication Critical patent/JP2002512989A5/ja
Application granted granted Critical
Publication of JP4648542B2 publication Critical patent/JP4648542B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000545584A 1998-04-24 1999-04-23 置換ポルフィリン Expired - Fee Related JP4648542B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8288198P 1998-04-24 1998-04-24
US60/082,881 1998-04-24
PCT/US1999/008905 WO1999055388A1 (en) 1998-04-24 1999-04-23 Substituted porphyrins

Publications (3)

Publication Number Publication Date
JP2002512989A JP2002512989A (ja) 2002-05-08
JP2002512989A5 true JP2002512989A5 (enExample) 2010-10-07
JP4648542B2 JP4648542B2 (ja) 2011-03-09

Family

ID=22174053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000545584A Expired - Fee Related JP4648542B2 (ja) 1998-04-24 1999-04-23 置換ポルフィリン

Country Status (10)

Country Link
US (1) US6479477B1 (enExample)
EP (1) EP1071474B1 (enExample)
JP (1) JP4648542B2 (enExample)
AT (1) ATE311206T1 (enExample)
AU (1) AU771259B2 (enExample)
CA (1) CA2329751C (enExample)
DE (1) DE69928655T2 (enExample)
DK (1) DK1071474T3 (enExample)
ES (1) ES2257858T3 (enExample)
WO (1) WO1999055388A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
AU771259B2 (en) 1998-04-24 2004-03-18 Aeolus Sciences, Inc. Substituted porphyrins
US6632808B1 (en) 1998-08-11 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of amyloid formation
CA2359116C (en) 1999-01-25 2009-03-17 National Jewish Medical And Research Center Substituted porphyrins
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
JP2003012547A (ja) * 2001-06-27 2003-01-15 Meiji Seika Kaisha Ltd インスリン依存性糖尿病の診断剤および治療剤
US20040132706A1 (en) * 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
CA2488500A1 (en) 2002-06-07 2003-12-18 Duke University Substituted porphyrins
EP1539751B1 (en) * 2002-07-15 2008-05-07 Scinopharm Taiwan, Ltd. Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides
GB2397067B (en) 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
WO2005000854A2 (en) * 2003-06-06 2005-01-06 Eukarion, Inc. Orally bioavailable low molecular weight metalloporphyrins as antioxidants
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US7807825B2 (en) 2004-02-09 2010-10-05 Duke University Substituted porphyrins
US7432369B2 (en) 2004-03-29 2008-10-07 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20080289053A1 (en) * 2007-05-15 2008-11-20 The Regents Of The University Of California Methods and systems for identifying modulators of longevity
WO2009095923A2 (en) * 2008-01-31 2009-08-06 Technion Research And Development Foundation Ltd Corroles for neuroprotection and neurorescue
CN102105146A (zh) 2008-05-23 2011-06-22 国立犹太保健医院 用于治疗与暴露于烷化物质有关的损伤的方法
EP2625180B1 (en) * 2010-10-06 2016-03-02 Aeolus Sciences, Inc. Porphyrin treatment of neurodegenerative diseases
EP2785339A4 (en) 2011-12-02 2015-11-25 Univ Colorado Regents NEUROLOGICAL TREATMENTS WITH METALOPORPHYRINE
US10646595B2 (en) * 2013-02-12 2020-05-12 The Governing Council Of The University Of Toronto Porphyrin compounds and their use as MRI contrast agents
WO2015034778A1 (en) 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating erectile dysfunction
CA2933166C (en) 2013-12-31 2020-10-27 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
WO2015112586A1 (en) 2014-01-22 2015-07-30 Duke University Methods of treating pruritus
KR101894575B1 (ko) * 2017-01-03 2018-09-04 주식회사 인트론바이오테크놀로지 돼지 피로부터 유래되지 않은 헴철을 제조할 수 있는 화학적 방법
EP4225759A1 (en) * 2020-10-05 2023-08-16 biolitec Unternehmensbeteiligungs II AG Tetrapyrrole-based compounds and their formulations for anti-microbial therapy

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465902A (en) * 1891-12-29 Cultivator
US2951799A (en) 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes using heterocyclic photosensitizers
EP0127797B1 (de) 1983-06-03 1987-06-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Markermoleküle für Fluoreszenz-Immuno-Assays sowie Verfahren und Zwischenprodukte zu deren Herstellung
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8429845D0 (en) 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US4758422A (en) 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
DK402785D0 (da) 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5248603A (en) 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
US4746735A (en) 1986-11-21 1988-05-24 The Dow Chemical Company Regiospecific aryl nitration of meso-substituted tetraarylporphyrins
DE3854872D1 (de) 1987-03-14 1996-02-22 Boehringer Ingelheim Int Humane Mangan-Superoxiddismutase (hMn-SOD)
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US4892941A (en) 1987-04-17 1990-01-09 Dolphin David H Porphyrins
US4851403A (en) 1987-04-21 1989-07-25 Johnson Matthey, Inc. Radiation sensitizers
US4885114A (en) 1987-04-22 1989-12-05 Barnes Engineering Co. Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same
US5051337A (en) 1987-06-10 1991-09-24 Director-General Of Agency Of Industrial Science And Technology Optical recording material
US5162519A (en) 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
DE3809671A1 (de) 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5109016A (en) 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
FR2632187B1 (fr) 1988-06-02 1990-09-14 Centre Nat Rech Scient Derives de metalloporphyrines, leur preparation, leur application en therapeutique et leur utilisation pour la preparation de molecules hybrides
US5171680A (en) 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
WO1990010694A1 (fr) 1989-03-06 1990-09-20 Suntory Limited Nouvelle superoxyde dismutase
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
EP0424033A3 (en) 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
US5236915A (en) 1990-05-31 1993-08-17 Health Research, Inc. Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents
EP0462836A3 (en) 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5217966A (en) 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5202317A (en) 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
AU8947791A (en) 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
GB9103991D0 (en) 1991-02-26 1991-04-10 Nat Res Dev Molecular electronic devices
FR2676738B1 (fr) 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
EP0598753B1 (en) 1991-07-19 1998-03-18 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5262532A (en) 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5212300A (en) 1991-09-12 1993-05-18 Sun Company, Inc. (R&M) Cyano- and polycyanometallo-porphyrins as catalysts for alkane oxidation
US5599924A (en) * 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
US5371199B1 (en) 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5493017A (en) 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
ATE201595T1 (de) * 1992-09-03 2001-06-15 Univ California Metallporphyrinzusammensetzungen
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
DE4305523A1 (de) * 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5747026A (en) 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
EP0758892A1 (en) 1994-05-13 1997-02-26 Monsanto Company Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
WO1996009053A1 (en) 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
CA2132690A1 (en) 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation
EP0831891B1 (en) 1995-06-07 2005-10-19 Duke University Oxidant scavengers
US6087493A (en) 1997-02-05 2000-07-11 Regents Of The University Of Texas System Porphyrin compounds as telomerase inhibitors
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
AU771259B2 (en) 1998-04-24 2004-03-18 Aeolus Sciences, Inc. Substituted porphyrins
CA2359116C (en) 1999-01-25 2009-03-17 National Jewish Medical And Research Center Substituted porphyrins
WO2001026655A1 (en) 1999-10-13 2001-04-19 Uab Research Foundation Metalloporphyrin treatment of neurologic disease
WO2001096345A1 (en) 2000-06-14 2001-12-20 Duke University Tetrapyrroles

Similar Documents

Publication Publication Date Title
JP2002512989A5 (enExample)
JP2021073272A5 (enExample)
CA2309154A1 (en) Substituted porphyrins
JP2001525359A5 (enExample)
HUP0104666A2 (hu) Új tiroid receptor ligandumok és II-es módszer
JP2004538303A5 (enExample)
JP2002519425A5 (enExample)
CA2299972A1 (en) Thyromimetic antiobesity agents
JP2002524449A5 (enExample)
JP2003501460A5 (enExample)
JP2002519434A5 (enExample)
JPH10503522A (ja) 化学療法剤とともに使用するための防御性プロスタグランジン
JP2003531118A5 (enExample)
JP2003535094A5 (enExample)
JP2004505047A5 (enExample)
JP2009533356A5 (enExample)
JP2005526144A5 (enExample)
JP2004516314A5 (enExample)
CA2675845A1 (en) Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
RU2003101319A (ru) Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
JP2003500450A5 (enExample)
JP2003519228A5 (enExample)
JP2002525323A5 (enExample)
JP2002520286A5 (enExample)
JP2002522501A5 (enExample)